Editorial: diabetes and obesity effects on lung function by Chen, Xiaofeng et al.
EDITORIAL
published: 16 July 2020
doi: 10.3389/fendo.2020.00462
Frontiers in Endocrinology | www.frontiersin.org 1 July 2020 | Volume 11 | Article 462
Edited and reviewed by:
Gaetano Santulli,










This article was submitted to
Clinical Diabetes,
a section of the journal
Frontiers in Endocrinology
Received: 22 May 2020
Accepted: 11 June 2020
Published: 16 July 2020
Citation:
Chen X-F, Yan L-J, Lecube A and
Tang X (2020) Editorial: Diabetes and
Obesity Effects on Lung Function.
Front. Endocrinol. 11:462.
doi: 10.3389/fendo.2020.00462
Editorial: Diabetes and Obesity
Effects on Lung Function
Xiao-Feng Chen 1, Liang-Jun Yan 2*, Albert Lecube 3* and Xiaoqiang Tang 4*
1 School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China, 2Department of
Pharmaceutical Sciences, University of North Texas System College of Pharmacy, University of North Texas Health Science
Center, Fort Worth, TX, United States, 3Obesity, Diabetes and Nutrition Research Group, Endocrinology and Nutrition
Department, Institut de Recerca Biomèdica de Lleida (IRBLleida), University Hospital Arnau de Vilanova de Lleida, Universitat
de Lleida, Lleida, Spain, 4 Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key
Laboratory of Biotherapy, West China Second University Hospital, Sichuan University, Chengdu, China
Keywords: diabetes, insulin, pulmonary disease, lung function, molecular mechanisms
Editorial on the Research Topic
Diabetes and Obesity Effects on Lung Function
Diabetes mellitus is a group of metabolic diseases characterized by persistent hyperglycemia which
prevalence and incidence have risen sharply worldwide (1, 2). In particular, over 90% of all diabetes
cases are type 2 diabetes mellitus (T2DM) (3, 4). Nowadays, studies have shown that absolute or
relative insufficient insulin secretion and impaired action of insulin signaling pathways are two of
the major causes of diabetes. Moreover, diabetes is a disease affecting a lot of organs such as kidney,
liver, eyes, and heart and there is also a growing body of evidence suggesting that the lung is also
one of the target organs in diabetes (5, 6). This special issue Research Topic, “Diabetes and Obesity
Effects on Lung Function” contains a collection of studies that aremainly focused on understanding
the association between diabetes and pulmonary diseases, and the underlying mechanisms. We
hope that the paper collected in this special issue would broaden our knowledge about diabetic
lung and facilitate the development of better disease management strategies.
Circadian rhythms are 24-h rhythms in physiology driven by the circadian clock system of the
suprachiasmatic nucleus located in the hypothalamus (7). Circadian rhythms are widely involved
in metabolism-related diseases (8, 9). As Sirtuins are adenine dinucleotide (NAD+)-dependent
histone deacetylases (10), it has been suggested that Sirtuins also play significant roles in regulating
diseases such as type 2 diabetes (11, 12). Zhou et al. provided a detailed review discussing the role of
circadian rhythms and Sirtuins in the diabetic lung. After an initial description of the histological
and functional changes that appears in the diabetic lung, they describe the circadian clock that
affects insulin secretion and insulin sensitivity and protects the diabetic lung against oxidative stress
and inflammation processes. Furthermore, they illustrated the potential regulatory mechanism
of Sirtuins (SIRT1, SIRT3, and SIRT6) in the lung of subjects with diabetes together with the
interactions between Sirtuins and the circadian clock. This work improves our understanding of
the circadian regulation of metabolic pulmonary diseases.
Wang et al. discussed the potential mechanisms involved in idiopathic pulmonary fibrosis
(IPF) contributed by diabetes and provided an overview of diabetic IPF. Specifically, they
concluded that diabetes is a risk factor and a marker of poor prognosis for IPF patients
through discussing epidemiology, pulmonary functional changes, and pathological changes.
Mechanistically, persistent hyperglycemia could destroy the alveolar epithelial cells or increase the
production of pro-inflammatory and pro-fibrotic factors.
Lung cancer remains the most common cancer (11.6% of all) and the leading cause of cancer
deaths, with over 1.7 million deaths worldwide in 2018 (13). Chin-Hsiao Tseng contributes with a
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retrospective cohort study examining the influence of insulin
on lung cancer in patients with type 2 diabetes. Surprisingly,
the study demonstrates that insulin use would accelerate the
progression of lung cancer. This study significantly improves the
understanding of lung cancer and introduces a warning signal
regarding insulin therapy in these patients.
Accumulating evidence has shown that disturbed sleep is
implicated in the physiopathology of type 2 diabetes (14, 15).
And sympathetic hyperactivity is associated with type 2 diabetes
as well as sleep apnea-hypopnea syndrome (SAHS). López-Cano
et al. concluded that intermittent hypoxia resulting from
sleep breathing disorders increases the sympathetic activity
in patients with type 2 diabetes, which in turn amplifies
the effect of hyperglycemia, increasing both cardiovascular
risk and microangiopathic diabetic complications. Thus,
a good sleep could help prevent and treat diabetes and
cardiovascular diseases.
Lung inflammation is also controlled by metabolic
regulators. The review paper submitted by Xu et al. focuses
on understanding the effect of oxidative stress and the AMPK-
Nrf2 pathway in pneumonia. Specifically, this study discusses
how ROS accumulation mediated by a pulmonary lesion or
metabolic diseases such as type 2 diabetes or obesity makes
the lung more susceptible to bacterial and viral infection. In
particular, activation AMPK-Nrf2 could ameliorate pneumonia
through its antioxidative effects.
In summary, papers collected in this special issue underline
the deleterious roles of diabetes mellitus andmetabolic regulators
in pulmonary diseases including idiopathic pulmonary fibrosis,
lung cancer, and pneumonia. It stresses that more attention
should be paid to illustrate the underlying mechanisms that may
provide invaluable insights into novel approaches for attenuating
diabetic lung injury in the future.
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